We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA's Critical Path Initiative Focuses on Biomarkers, Clinical Trials
FDA's Critical Path Initiative Focuses on Biomarkers, Clinical Trials
March 17, 2006
The FDA has unveiled its long-awaited Critical Path Opportunities List, focusing on projects that will advance the use of biomarkers and streamline clinical trials.